Biotech, Medtech & eHealth
Unique expertise to help Biotech, Medtech & eHealth
innovators, at any stage of their development
Building on 25+ years of passion & experience, we have developed a unique combination of capabilities in strategy, financial advisory & transactions
Experts in maximizing the value of your company & assets, leveraging our deep understanding of Science & Business
We guide you to build your Spin Off or Start Up
- Assessment of preclinical & clinical data
- Assessment of IP package
- Business plan development
- Funding strategy
- Access & commercialization strategy
We partner with you to maximize the value of your asset
- From discovery / pre-clinical to Investigational New Drug (IND)
- Clinical development strategy, including target indication prioritization
- Regulatory strategy including specific pathways and status
- Value maximization / De-risking strategy
We help you commercialize your assets across key markets
- Most appropriate commercialization approach
- Business model design and customization to market specificities
- Go-to-Market model (Build / Buy / Partner)
- Market Access & Pricing strategy
Experts in transforming your innovation into a compelling equity story, leveraging our knowledge of investors
We help you to define the best value creation pathway of your innovation
- Definition of value inflection points
- Exit strategy & return for investors assessment
We support you throughout your fundraising journey
- Review, challenge & extract the value of your data set
- Reviewing / Building of Business Plan
- Customized package to create interest & convince investors
- Coaching for investor pitch
- Investor prioritization according to funding strategy
- Full support until closure of fundraising
Partners throughout your transaction journey, leveraging our negotiation skills & relationship with pharma companies
We ensure you make the most out of partnering deals / asset sales
- Review, challenge & extract the value of your data set
- Asset valuation (including primary research outcomes)
- Preparation of appealing materials to create interest & convince partners
- Access to a vast network of relevant partners across Pharmaceutical & Medical Device industries
- Prioritize & target the best partners
- Clinical development strategy, including target indication prioritization
- Regulatory strategy including specific pathways & status
- Value maximization / De-risking strategy
We support you on your M&A journey for a successful company/asset acquisition or sale
- Vendor Due Diligence
- Company valuation
- Access to vast network of buyers across Private Equity, Pharmaceutical & Medical Device industries
- Prioritize & target the best buyers
- Full support from first contact through deal closing
They havetrusted us

Abivax
Afyren
Aimmune
Alnylam
Beigene
Biomunex
Butterfly Therapeutics
Clevexel
Cold Genesys
DBV Technologies
Dermavant
Edwards Lifesciences
EverImmune
FreeOx
Gabi Smartcare
Galapagos
GamaMabs
Genosafe
Gustave Roussy Transfer
Innate Pharma
Insulet
Inventiva
I-Sep
ITCC
Locemia Solutions
Macopharma
MedinCell
Metronom Health
Neos Sugery
Nervosave
Neurim
Nexbiome
Orano Med
OSE Immunotherapeutics
Parean Biotech
PDC*Line
Pelago Biosciences
Perha Pharmaceuticals
Prometheus
Seattle Genetics
TreeFrog Therapeutics
Valbiotis
Vaxinano
Yposkesi
Ziwig
Why chooseAEC Partners ?
Strong scientific, clinical, market access & commercial expertise
Vast network of Pharmaceutical, Medical Device companies & Investors
Track record in supporting Biotech, Medtech & eHealth companies for 25+ years
Flexible remuneration model
Some of the transactionswe have supported



















